Zipalertinib demonstrated 38% ORR in a phase 1⁄2 trial, with 23% grade 3 or higher adverse events, and received breakthrough therapy designation (BTD) for use in previously treated patients with EGFR exon 20 insertion-positive NSCLC [39,47]. Here, EGFR is linked to non-small cell lung carcinoma.